Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. - Wikidata - wikimedia - TriplyDB

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.

http://www.wikidata.org/entity/Q33180853

about

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy Acute Cyclophosphamide Hemorrhagic Myopericarditis: Dilemma Case Report, Literature Review and Proposed Diagnostic Criteria Cardiac toxicity in cancer survivors Evaluation and management of patients with heart disease and cancer: cardio-oncology Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.Noninvasive diagnosis of chemotherapy related cardiotoxicity Cardio-oncology: a new medical issue.Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.Assessment of cardiotoxicity with cardiac biomarkers in cancer patients.Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent tr Morphine enhances doxorubicin-induced cardiotoxicity in the rat.Heart repolarization changes after anthracycline therapy in the children with cancer Chemotherapy-induced cardiotoxicity.Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy.Cardiac troponins as biomarkers of drug- and toxin-induced cardiac toxicity and cardioprotection.Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic r Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients Cardiovascular effects in childhood cancer survivors treated with anthracyclines.Cardiovascular toxicities from systemic breast cancer therapy.Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment Perioperative myocardial infarction in noncardiac surgery: the diagnostic and prognostic role of cardiac troponins.Cardiac dysfunction after cancer treatment.A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer.Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.Biochemical markers of myocyte injury in heart failure Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes Cardiac toxicity of high-dose chemotherapy.Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity.An Alpha-1A Adrenergic Receptor Agonist Prevents Acute Doxorubicin Cardiomyopathy in Male Mice.Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.Present and future biochemical markers for detection of acute coronary syndrome.Anthracycline cardiotoxicity.

P2860

Q21284978-AF128BF6-7A54-4B10-A476-A34D4652F53A Q26743433-D6C9F575-6A9C-4CB6-BDCB-B08E0DE976F3 Q26775467-78104E8E-3D89-49F1-8594-499A2FAFE478 Q26851957-59D337B3-6FF2-4861-9EDC-33BC4308D043 Q26998273-725771B7-3355-4556-B184-F8CDE37F30DA Q27007849-AD3694F1-E531-4458-803B-6EEFAFF1FA82 Q27027354-CCF1E74F-85F0-49C2-96E3-0F6E700C3D13 Q28270920-2DF52E13-0089-4A34-9D69-E3424A971261 Q30427656-8E1297FA-EF83-4108-994C-F0DD3C3BE86D Q30461444-AD8EEDAF-B362-42F2-BE3C-026B09FC55C0 Q30471284-2AACB4CE-F916-4CF0-AD53-20CAFCC53CF7 Q33816471-26A270DE-E8C6-40B3-9EF4-B47A37CD4584 Q33840140-D6833CEB-CE71-419F-B4A4-9C7AB8B3C5E9 Q33896047-77D935C4-0405-49EA-B8BE-4A92636220D8 Q33973013-C36D5895-5200-4AAF-906C-1165A6E2419C Q34048494-3C60AD80-753E-46A8-A24F-EA1323BB381C Q34234872-612F2CD7-04C2-430F-B7E6-BCD5AB1C01A3 Q34258080-7F6B5223-F263-4007-8F3E-3784277B23A4 Q34466688-025C1124-D8E5-483C-B073-A6116C19BECC Q34550487-AA6C51A8-4CA2-4C38-A79D-7B3FDA81F702 Q34560383-CB6CCF50-DC87-4D5F-BE96-55D39171F066 Q34570840-267BEF56-9817-490B-BB58-082F0650DA55 Q34572109-020C3AF1-0399-4705-B1FC-84B2B76BE5F5 Q34630349-8C192180-3258-401F-8C04-B42CC638ED2D Q34639876-0CBA8605-9439-471E-B86B-8027CD326086 Q34696254-BA519B10-BC2B-4FAF-917E-2356AF7E73DA Q35039549-929C41F5-7F04-48EE-830B-0CCF2E963EAA Q35232931-54829742-ECBA-4327-9E02-C2E4A79C9A9A Q35588736-0EFEDBFF-AFA6-46EB-A721-6864C1A02B76 Q35623306-8993A2D1-B06C-4802-BF3F-8E789F913CD5 Q35887596-60C40D41-6D97-48BD-B595-C24575456AA2 Q35925266-9682BAB3-AA65-4C27-96B7-C6CF4969617A Q35949084-4C1713C8-2ECA-4255-A85D-10CCDDA72AB3 Q36150546-73FC24B7-5D81-4468-AFEA-1B7D3A611817 Q36247553-5EA9C015-B51D-43B7-872C-49C1FF717119 Q36339976-6300CADF-AEA7-46CE-95F3-1FD88F785799 Q36410651-1706D986-3DE7-469C-A388-C3683261F341 Q36451899-E92F771C-84A5-47D5-835B-07C80C18F706 Q36624223-0EFC7620-C52F-4CA7-8632-19CF3243B93C Q36624983-D7E845C6-8B38-485F-96ED-0DC556890428

P2860

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.

http://www.wikidata.org/entity/Q33180853

description

2000 nî lūn-bûn

@nan

2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Left ventricular dysfunction p ...... after high-dose chemotherapy.

@ast

Left ventricular dysfunction p ...... after high-dose chemotherapy.

@en

type

label

Left ventricular dysfunction p ...... after high-dose chemotherapy.

@ast

Left ventricular dysfunction p ...... after high-dose chemotherapy.

@en

prefLabel

Left ventricular dysfunction p ...... after high-dose chemotherapy.

@ast

Left ventricular dysfunction p ...... after high-dose chemotherapy.

@en

P1433

Q33180853-079B19E6-0991-4BEA-A959-1FC02446A38C

P1476

Q33180853-97426782-FEF7-4426-9508-0F949DD417F2

P2093

Q33180853-13ADB267-901D-4861-BBCF-7DC6CAB7B996

Q33180853-1EBF842A-BE01-4319-A80D-995DA0F0A745

Q33180853-3F3BBF2D-32FC-4B92-83A2-2FC27905EF92

Q33180853-438581EE-7963-4BE1-82E7-85534058E034

Q33180853-5096D416-6862-4D4F-B51F-5449D8D1B600

Q33180853-5212B4E7-43C9-43DB-B4C9-B99F6A13BC5E

Q33180853-9DE54EB5-807B-4BF2-A53A-51F8C8CC8829

Q33180853-C0D42AAD-767C-4BAC-980C-7B1E82FC3A1E

Q33180853-D2FAED5F-4B25-438F-9212-5EBCBDD2122C

Q33180853-EB3C033B-5075-43B2-939C-D1F2458CB534

P304

Q33180853-6CB7AAEE-0726-4D93-ACEB-010822EF826E

P31

Q33180853-A0205CD8-B660-41C0-A89E-F256056621BF

P356

Q33180853-985C3444-CC50-4DE1-A45A-154074B68970

P407

Q33180853-9F332324-5185-4EB4-AD60-E92670F9004C

P433

Q33180853-A58E39F1-15BB-4231-B3C9-01A4C076F017

P478

Q33180853-6A195BAF-8C7E-45A6-AC6D-55D4B644DF06

P577

Q33180853-4DA0D2E0-1A11-4ABB-BBD4-FE3F05034FA1

P698

Q33180853-70746E4D-1EDA-4B59-8EB7-9FAA23DFABED

P921

Q33180853-A3F7AC2E-FFBB-4460-89CE-005912C098EF

P356

S0735-1097(00)00748-8

P1433

Journal of the American College of Cardiology

P1476

Left ventricular dysfunction p ...... after high-dose chemotherapy.

@en

P2093

Cardinale D

http://www.w3.org/2001/XMLSchema#string

Cinieri S

http://www.w3.org/2001/XMLSchema#string

Cipolla CM

http://www.w3.org/2001/XMLSchema#string

Civelli M

http://www.w3.org/2001/XMLSchema#string

Fiorentini C

http://www.w3.org/2001/XMLSchema#string

Lamantia G

http://www.w3.org/2001/XMLSchema#string

Martinelli G

http://www.w3.org/2001/XMLSchema#string

Martinoni A

http://www.w3.org/2001/XMLSchema#string

Sandri MT

http://www.w3.org/2001/XMLSchema#string

Tricca A

http://www.w3.org/2001/XMLSchema#string

P304

517-522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0735-1097(00)00748-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2000-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10933366

http://www.w3.org/2001/XMLSchema#string

P921